421 related articles for article (PubMed ID: 31680842)
1. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.
Grieco M; Giorgi A; Gentile MC; d'Erme M; Morano S; Maras B; Filardi T
Front Neurosci; 2019; 13():1112. PubMed ID: 31680842
[TBL] [Abstract][Full Text] [Related]
2. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
3. Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.
Pelle MC; Zaffina I; Giofrè F; Pujia R; Arturi F
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511061
[TBL] [Abstract][Full Text] [Related]
4. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C
Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes.
Gault VA; Hölscher C
Peptides; 2018 Feb; 100():101-107. PubMed ID: 29412810
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
7. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat.
Han L; Hölscher C; Xue GF; Li G; Li D
Neuroreport; 2016 Jan; 27(1):23-32. PubMed ID: 26555034
[TBL] [Abstract][Full Text] [Related]
8. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
9. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.
Reich N; Hölscher C
Front Neurosci; 2022; 16():970925. PubMed ID: 36117625
[TBL] [Abstract][Full Text] [Related]
10. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain.
Bae CS; Song J
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165354
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.
Muscogiuri G; DeFronzo RA; Gastaldelli A; Holst JJ
Trends Endocrinol Metab; 2017 Feb; 28(2):88-103. PubMed ID: 27871675
[TBL] [Abstract][Full Text] [Related]
12. Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.
Vergès B; Aboyans V; Angoulvant D; Boutouyrie P; Cariou B; Hyafil F; Mohammedi K; Amarenco P
Cardiovasc Diabetol; 2022 Nov; 21(1):242. PubMed ID: 36380358
[TBL] [Abstract][Full Text] [Related]
13. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.
Hölscher C
CNS Drugs; 2012 Oct; 26(10):871-82. PubMed ID: 22938097
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.
Lin TK; Lin KJ; Lin HY; Lin KL; Lan MY; Wang PW; Wang TJ; Wang FS; Tsai PC; Liou CW; Chuang JH
Front Mol Neurosci; 2021; 14():697440. PubMed ID: 34305527
[TBL] [Abstract][Full Text] [Related]
15. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
Hölscher C
Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
[TBL] [Abstract][Full Text] [Related]
16. The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases.
Cheng D; Yang S; Zhao X; Wang G
Drug Des Devel Ther; 2022; 16():665-684. PubMed ID: 35340338
[TBL] [Abstract][Full Text] [Related]
17. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
Hölscher C
J Endocrinol; 2014 Apr; 221(1):T31-41. PubMed ID: 23999914
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs
Ikeda Y; Nagase N; Tsuji A; Kitagishi Y; Matsuda S
World J Biol Chem; 2021 Nov; 12(6):104-113. PubMed ID: 34904048
[TBL] [Abstract][Full Text] [Related]
19. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases.
Hölscher C
Front Synaptic Neurosci; 2022; 14():955258. PubMed ID: 35965783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
